Amgen today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
MRV Research
Data on Merck’s MK-3475 from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
CHICAGO, Jun 2, 2014 (Canada NewsWire via COMTEX) — MK-3475 as monotherapy shows estimated overall survival rates of 69 percent at one year across 411 advanced melanoma patients with varying stages of disease and prior therapy
Durable responses and consistent tolerability profile observed across doses, including patients with or without prior ipilimumab therapy
Blistering sunburns in adolescence linked with 80% higher risk for melanoma
The risk for developing melanoma is significantly linked with severe sunburns before age 20 years among young white women, according to recent findings.
Specifically, the risk for onset of melanoma in adulthood was increased by 80% among those who suffered at least five blistering sunburns between the ages of 15 and 20 years.
Five Blistering Sunburns Up Melanoma Risk by 80 Percent
The risk of developing the most deadly form of skin cancer, melanoma, is more closely related to sun exposure in early life than in adulthood in young Caucasian women, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.